Skip to main content
. 2017 Feb 10;9:20. doi: 10.3389/fnagi.2017.00020

Table 1.

GWAS studies and their meta-analyses that identified 24 risk loci included in this review.

Study Ancestry Number of cases
Initial phase (cases vs. controls) Replication phase (cases vs. controls)
Nalls et al., 2014# European Initial phase—*USA, *France, *Germany, *Iceland, *Netherlands, *UK, *23andMe Replication phase—*US, *UK, *France, *Germany, *Greece, *Netherlands, *NeuroX 13,708 vs. 95,282 5,353 vs. 5,551
Vacic et al., 2014 Ashkenazi Jewish Initial phase—*Israel, *US Replication phase—*Israel, *US 1,130 vs. 2,611 306 vs. 2,583
Hill-Burns et al., 2014 European Initial phase—*US Replication phase—not reported 1,565 sporadic cases + 435 familial cases vs. 1,986 controls 1,528 sporadic cases + 707 familial cases vs. 796 controls
Lill et al., 2012# Initial phase—*US Replication phase—European and Asian 2,197 vs. 2,061 Up to 98,080
Pankratz et al., 2012# European 4,238 vs. 4,239 3,738 vs. 2,111
Do et al., 2011 European 3,426 vs. 29,624 Not applicable
Nalls et al., 2011# Initial phase—*France, *Germany, *UK, *US Replication phase—*US, *France, *Germany, *Netherlands, *Iceland, *UK 5,333 vs. 12,019 7,053 vs. 9,007
Hamza et al., 2010 European 2,000 vs. 1,986 Up to 1,447 vs. 1,468
Saad et al., 2011 European 1,039 vs. 1,984 3,232 vs. 7,064
Spencer et al., 2011 Initial phase—*UK Replication phase—*France 1,705 vs. 5,175 1,039 vs. 1,984
Edwards et al., 2010 European 1,752 vs. 1,745 Not applicable
Satake et al., 2009 Japanese 988 vs. 2,521 933 vs. 15,753
Simon-Sanchez et al., 2009 European 1,713 vs. 3,978 3,361 vs. 4,573
*

country of recruitment, if specified.

#

meta-analysis.

Data compiled from the GWAS catalog database and PDgene (Lill et al., 2012; Nalls et al., 2014; Welter et al., 2014).